In Brief: Alpha Therapeutic's AlphaNineSD
Alpha Therapeutic's AlphaNineSD: Solvent Detergent Treated/Virus Filtered Factor IX product for prevention and control of bleeding in Hemophilia B patients approved by FDA June 7, the Los Angeles-based company announced July 11. The product is the first plasma-derived coagulation factor concentrate to incorporate more than one method of viral reduction, the company says. Previously AlphaNine was only solvent detergent treated. The new Factor IX now also includes a nanofiltration process for removing viruses. The two processes together reduce HIV-1 by 12 logs, HIV-2 by 6 logs, non-lipid-enveloped agents by 4 logs and markers for hepatitis B and C by 5 logs, Alpha Therapeutic notes. The new version of AlphaNine will be available in July. Alpha Therapeutic announced in March that is also has implemented additional product lot testing of the final product container as another safety step. Alpha Therapeutics sold 80 mil. units of AlphaNine last year..
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth